Analysts expect that Recro Pharma Inc (NASDAQ:REPH) will post $17.32 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $17.00 million and the highest estimate coming in at $17.64 million. Recro Pharma reported sales of $18.74 million in the same quarter last year, which would suggest a negative year over year growth rate of 7.6%. The company is scheduled to issue its next quarterly earnings results on Thursday, May 10th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $17.32 million for the current year, with estimates ranging from $72.00 million to $78.00 million. For the next year, analysts anticipate that the firm will report sales of $113.57 million per share, with estimates ranging from $102.50 million to $122.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Recro Pharma.
Recro Pharma (NASDAQ:REPH) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.22. The firm had revenue of $19.04 million during the quarter, compared to analysts’ expectations of $12.88 million. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%.
In other Recro Pharma news, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total transaction of $115,120.32. Following the completion of the sale, the insider now directly owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total transaction of $2,014,000.00. The disclosure for this sale can be found here. Corporate insiders own 21.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the business. Lyon Street Capital LLC acquired a new position in shares of Recro Pharma in the 4th quarter valued at $3,362,000. Wells Fargo & Company MN lifted its holdings in shares of Recro Pharma by 42.5% in the third quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 7,308 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Recro Pharma by 14.2% in the second quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock worth $4,501,000 after buying an additional 79,520 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after buying an additional 144,676 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Recro Pharma by 787.4% in the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock worth $911,000 after buying an additional 114,960 shares in the last quarter. 57.85% of the stock is owned by institutional investors and hedge funds.
NASDAQ REPH traded up $0.28 during trading hours on Tuesday, hitting $11.01. 129,273 shares of the company’s stock traded hands, compared to its average volume of 373,035. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.55 and a current ratio of 1.75. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $12.23.
TRADEMARK VIOLATION NOTICE: “$17.32 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.wkrb13.com/2018/04/01/17-32-million-in-sales-expected-for-recro-pharma-inc-reph-this-quarter.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.